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Patients who have common variable immunodeficiency (CVID) and granulomatous/
lymphocytic interstitial lung disease (GLILD) are at high risk for early mortality and B cell 
lymphomas. Infection with human herpes virus type 8 (HHV8), a B cell lymphotrophic virus, 
is linked to lymphoproliferative disorders in people who have secondary immunodeficiencies. 
Therefore, we determined the prevalence of HHV8 infection in CVID patients with GLILD. 
Genomic DNA isolated from peripheral blood mononuclear cells was screened by nested- and 
real time-quantitative PCR (QRT-PCR) for the presence of HHV8 genome. It was positive in 
6/9 CVID patients with GLILD (CVID-GLILD), 1/21 CVID patients without GLILD (CVID-control), 
and no patients receiving intravenous gamma globulin (
 
n
 
 
 
 
 
 13) or normal blood donors 
(
 
n
 
 
 
 
 
 20). Immunohistochemistry (IHC) demonstrated expression of the latency-associated 
nuclear antigen-1 (LANA-1) in the biopsies of the lung, liver, and bone marrow of four 
patients with CVID-GLILD. One CVID-GLILD patient developed a B cell lymphoma during the 
course of the study. QRT-PCR demonstrated high copy number of HHV8 genome and IHC 
showed diffuse staining for LANA-1 in the malignant lymph node. HHV8 infection may be 
an important factor in the pathogenesis of the interstitial lung disease and 
lymphoproliferative disorders in patients with CVID.
 
Common variable immunodeficiency (CVID) is
a primary immunodeficiency of unknown etiol-
ogy that is characterized by a low serum IgG and
the inability to make specific antibodies in re-
sponse to immunization or infection (1). Defects
in cellular immunity, which occur in approxi-
mately one third of patients, likely contribute to
their susceptibility to conventional and opportu-
nistic pathogens. We analyzed the prevalence,
clinical findings, and natural history of diffuse
parenchymal  lung disease in 69 patients with
CVID (2). Granulomatous or lymphocytic inter-
stitial lung disease (GLILD) was present in 
 
 
 
20%
of patients who had CVID; its presence por-
tended a poor prognosis (2). Patients who had
CVID and GLILD exhibited T cell lymphope-
nia, splenomegaly, and were at high risk for
B cell lymphoproliferative diseases (e.g., non-
Hodgkin’s lymphoma [NHL]), which occurred
in nearly 30% of these patients. This constellation
of clinical findings in this cohort of patients raised
the question of whether GLILD was a unique
disease entity with a common etiologic basis.
Human herpesvirus type 8 (HHV8) is a
 
 
 
-herpes virus that also is known as Kaposi’s sar-
coma (KS)–associated virus (3). In the context
of secondary immunodeficiencies, such as HIV-1
infection or organ transplantation, HHV8 is an
opportunistic pathogen that is linked to the de-
velopment of lymphoproliferative diseases (e.g.,
primary effusion lymphoma and multicentric
Castleman’s disease; reference 4). The proclivity
of HHV8 to cause lymphoproliferative disor-
ders in the setting of immunodeficiency, together
with our observations that CVID-GLILD pa-
tients were highly susceptible to lymphoprolif-
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erative disease, prompted us to determine if HHV8 infection
was present in the blood and affected tissues of patients with
CVID and GLILD.
 
RESULTS AND DISCUSSION
CVID patients with GLILD exhibit CD4 lymphopenia
 
The following groups of people were recruited prospectively
for participation in the study (Table I): normal blood donors
(
 
n
 
 
 
 
 
 20); patients receiving intravenous gamma globulin but
without CVID (
 
n
 
 
 
 
 
 13); CVID patients with GLILD (CVID-
GLILD 
 
n
 
 
 
 
 
 9); and CVID patients without GLILD (CVID-
control: 
 
n 
 
 
 
 21). All patients with CVID-GLILD under-
went an open lung biopsy that demonstrated one or more
of the following histologic patterns: granulomatous disease,
lymphocytic interstitial pneumonitis, lymphoid hyperpla-
sia, or follicular bronchiolitis. These different histologic pat-
terns frequently are present concomitantly in the individual
lung biopsies of CVID patients (2), which suggests that these
are histologic variations of the same disease. Therefore, we
have collectively termed these histologic patterns as GLILD.
Lymphocyte enumeration studies demonstrated that patients
with CVID-GLILD exhibited a 
 
 
 
40% reduction in the
numbers of CD4
 
 
 
 T cells compared with CVID-control pa-
tients (P 
 
 
 
 0.03; Table II). There was no difference in the
numbers of CD8
 
 
 
 T cells or B cells between the two
groups.
 
Most patients with CVID-GLILD are infected with HHV8 
as determined by nested PCR and QRT-PCR 
 
Genomic DNA isolated from PBMCs was used as the tem-
plate to screen for HHV8 sequences by nested PCR from
all participants in the study (Fig. 1). Presumptive evidence
of HHV8 infection required that the PCR generated am-
plicons from ORF 26 and ORFK9. The prevalence of
HHV8 infection among the CVID-GLILD patients was
markedly higher than among the CVID-control patients (6/9
versus 1/21; P 
 
 
 
 0.0009; Fig. 1). No normal blood do-
nors (
 
n
 
 
 
 
 
 20; Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20050381/DC1) or patients receiving in-
travenous gamma globulin for other disorders (
 
n 
 
 
 
 13)
were positive for HHV8 infection by nested PCR. The
nested PCRs for HHV8 ORF 26 and ORFK9 were per-
formed on three separate occasions for each subject, and the
results (negative or positive for HHV8 amplicons) were
consistent. At no time did we observe HHV8 amplicons in
our negative control or in patient samples that initially
tested negative. DNA sequencing of the ORF26 amplicon
was performed in five patients. Analysis of the DNA se-
quences at strain-variable positions established that all pa-
tients were infected with the A strain of HHV8 (1086-C,
 
Table I.
 
Study population
 
Group Gender Age
 
female/male mean 
 
 
 
 SEM
 
CVID-control  14/7 47.2 
 
 
 
 3.5
CVID-GLILD 4/5 42.1 
 
 
 
 4.4
XLA 0/4 36.5 
 
 
 
 4.0
Other hypogammaglobulinemia 2/4 50.4 
 
 
 
 7.5
SCID 1/0 19.0
WAS 0/1 27.0
HIM 0/1 64.0
NBD 8/12 33 
 
 
 
 2.8
 
HIM, hyper IgM syndrome; NBD, normal blood donor; SCID, severe combined 
immunodeficiency; WAS, Wiskott-Aldrich syndrome; XLA, X-linked agammaglobulinemia.
 
Table II.
 
Lymphocyte enumeration in CVID patients
 
Variables CVID-GLILD CVID-control  p-value
 
n 
 
 
 
 9n  
 
 
 
 21
 
CD3
 
 
 
825.9 
 
 
 
 173.2 1,136.0 
 
 
 
 95.5 0.1254
CD3
 
 
 
/CD4
 
 
 
381.4 
 
 
 
 66.4 653.1 
 
 
 
 61.4 0.0319
CD3
 
 
 
/CD8
 
 
 
429.2 
 
 
 
 136.3 475.5 
 
 
 
 68.2 0.2995
CD19 143.3 
 
 
 
 51.4 198.9 
 
 
 
 35.7 0.2887
Figure 1. Detection of HHV8 genomes by nested PCR from PBMCs. 
Dotted lines separate patient/subject groups. The cohorts of patients 
included: “Normal” (normal blood donors), “IVIG” (patients receiving 
intravenous immunoglobulin for disorders other than CVID), “CVID-
control” (CVID patients without GLILD), and “CVID-GLILD” (CVID patients 
with GLILD).   (lane 12) is BCBL-1, an HHV8-infected B cell lymphoma 
cell line (positive control; lane1) is an H2O template negative control. 
ORF26 and ORFK9 indicate HHV8 open reading frames 26 and K9, 
respectively.  -actin indicates PCR of patient DNA using primers specific 
for  -actin. HHV8 amplicons were detected from DNA by nested PCR 
(PBMC DNA) or nonnested PCR (BCBL-1 DNA [lane 12]). White lines 
indicate that intervening lanes have been spliced out. 
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1094-G, 1132-A, 1139-A, 1168-C, 1173-G). This is the
most prevalent strain in the United States and accounts for
 
 
 
60% of HHV8 infections (5). Results using real time-
quantitative PCR (QRT-PCR) confirmed the results ob-
tained by nested PCR, and demonstrated variable copy
numbers of HHV8 genome in the DNA derived from PB-
MCs (Table III). QRT-PCR was consistently negative for
HHV8 infection on subjects that tested negative for HHV8
infection by nested PCR (unpublished data).
 
Detection of LANA-1 by IHC in tissues from patients 
with CVID-GLILD
 
Using formalin-fixed, paraffin-embedded tissue biopsies (lung,
liver, lymph nodes, bone marrow, small intestine), we per-
formed immunohistochemistry (IHC) to detect the LANA-1
in the available tissue biopsies of five patients with CVID-
GLILD (Fig. 2; Table III). LANA-1 was chosen because it is
expressed in the proliferative lesions that are known to be asso-
ciated with HHV8 infection (4). Three patients demonstrated
evidence of HHV8 infection by IHC (Table III). HHV8 in-
fection was detected in CVID-GLILD patients by IHC in
multiple tissues, including lung, liver, lymph node, and bone
marrow. QRT-PCR confirmed the presence of HHV8 ge-
nome in all tissues that were positive for LANA-1 by IHC.
One CVID-GLILD patient (patient 42), died from gran-
ulomatous hepatitis just before the initiation of this study.
IHC for LANA-1 of this patient’s liver biopsy demonstrated
that many of the hepatocytes were infected with HHV8
(Fig. 2 G). Insufficient liver tissue precluded an analysis of
this liver biopsy by QRT-PCR. Liver biopsies from three
other patients in the prospective CVID-GLILD cohort of
patients also demonstrated granulomatous hepatitis. These
biopsies were positive by nested and QRT-PCR for HHV8
genome, but negative for LANA-1 by IHC. Other tissue bi-
opsies demonstrated evidence of HHV8 infection by nested
and QRT-PCR, but were negative for LANA-1 by IHC;
this reflected the relative insensitivity of IHC to detect evi-
dence of HHV8 infection (Table III).
During the course of the study, B cell lymphomas oc-
curred in 22% (2 of 9) of CVID-GLILD patients (B cell NHL
in patient 11 and B cell lymphoma of mucosal-associated
lymphoid tissue [MALT] in patient 53). In patient 11, several
lines of evidence suggested that HHV8 infection contributed
to the development of the lymphoma. HHV8 infection of
the malignant lymph node was demonstrated by diffuse stain-
ing for LANA-1 by IHC (Fig. 2 C) and a conspicuously high
copy number of HHV8 genome by QRT-PCR (
 
 
 
15,000
copies/
 
 
 
g DNA; Table III). Multiple tissues were infected by
 
Table III.
 
HHV8 copy number in HHV8-infected patients
 
Patient no. Tissue Diagnosis Mean HHV8 copy no.
 
 
 
 
 
 
 
SD (95% confidence interval) IHC
 
(number/
 
 
 
g DNA)
 
23 PBMC CVID-control  42.0 
 
 
 
 20.6 (21.8–62.2) NA
10 PBMC
 
a
 
CVID-GLILD  43.5 
 
 
 
 16.5 (27.3–59.7)
 
NA
 
11 PBMC
 
a
 
CVID-GLILD  12.3 
 
 
 
 8.7 (3.8–20.7)
 
NA
 
16 PBMC CVID-GLILD 16.8 
 
 
 
 5.7 (11.2–22.3)
 
NA
 
27 PBMC CVID-GLILD  19.7 
 
 
 
 9.2 (10.7–28.7)
 
NA
 
29 PBMC
 
a
 
CVID-GLILD  28.8 
 
 
 
 12.7 (16.3–41.2)
 
NA
 
NA lung
 
b
 
HIV-1, 
 
 
 
KS  255 
 
 
 
 141 (116–393)
 
 
 
10 small intestine CVID-GLILD  633 
 
 
 
 501 (142–1,123)
 
 
 
10 colon CVID-GLILD  286 
 
 
 
 117 (171–401)
 
 
 
10 bone marrow CVID-GLILD  414 
 
 
 
 119 (297–531)
 
 
 
10 liver CVID-GLILD  375 
 
 
 
 264 (117–634)
 
 
 
10 lung CVID-GLILD  405 
 
 
 
 203 (206–604)
 
 
 
11 liver CVID-GLILD  434 
 
 
 
 11 (423–445)
 
 
 
11 lung CVID-GLILD  17 
 
 
 
 7 (10–24)
 
 
 
11 lymph node CVID-GLILD (NHL)   15,356 
 
 
 
 1,100 (14,279–16,434)
 
 
 
16 lung CVID-GLILD  5 
 
 
 
 3 (1.7–7.6)
 
 
29 lung CVID-GLILD  65    41 (25–106)  
51 lung CVID-GLILD  48    22 (26–70)  
51 lymph node CVID-GLILD  19   12 (7–32)  
51 liver CVID-GLILD  87    73 (16–159)  
aPatients with infection in PBMCs and tissues.
bKaposi’s sarcoma (positive control).
NA, not applicable.HUMAN HERPESVIRUS 8 IN COMMON VARIABLE IMMUNODEFICIENCY | Wheat et al. 482
HHV8 as determined by QRT-PCR and IHC (lymph node,
lung) or QRT-PCR alone (liver). The malignant lymph
node was negative for EBV infection as determined by in situ
hybridization for EBV-encoded small RNAs. Finally, the
GLILD and granulomatous hepatitis preceded the develop-
ment of the NHL in this patient by  3 yr. Evidence for a
role of HHV8 infection in the development of the MALT
(patient 53) was equivocal. Examination of the malignant tis-
sue from the MALT lymphoma was positive for HHV8 in-
fection as determined by nested PCR, but not QRT-PCR
or IHC (Fig. 2 H). The genomic DNA from the PBMCs of
patient 53 also was negative for HHV8 infection by nested
PCR (Fig. 1). Because of the ambiguous results in patient 53,
we did not score this patient as infected with HHV8 in the fi-
nal analysis. The MALT lymphoma also was negative for
EBV-encoded small RNAs by in situ hybridization.
With the advent of high-dose intravenous gamma globu-
lin therapy, noninfectious complications of CVID are an in-
creasing cause of morbidity and mortality in this group of pa-
tients (6). In particular, B cell lymphomas and progressive
interstitial lung disease are the major causes of death in this
population (1, 2, 7). CVID patients with GLILD exhibit lym-
phocytic infiltration of the lung parenchyma, splenomegaly,
diffuse lymphadenopathy, CD4 lymphopenia (2, 8), and have
evidence of HHV8 infection in several organ systems (Fig. 2;
Table III). We hypothesize that GLILD represents the pulmo-
nary component of more generalized lymphoproliferative dis-
ease that is promulgated by infection with HHV8. In addition
to the lymphoproliferative disease, our data suggest that the
granulomatous hepatitis, which is found frequently in CVID-
GLILD patients (2, 8), may be caused by HHV8 infection.
The finding that HHV8 is able to infect cells in several dif-
ferent organ systems in patients with CVID-GLILD is in agree-
ment with recent observations on the host range of HHV8.
Bechtel et al. (9) demonstrated that HHV8 is able to infect an
assortment of human and nonhuman cell lines of epithelial, en-
dothelial, and mesenchymal origin. Additionally, we recently
reported the presence of HHV8 in a variety of cell types in the
plexiform lesions of patients with primary pulmonary hyperten-
sion (10). In total, these observations suggest that the host range
for HHV8 infection may be broader than previously believed.
Earlier studies indicate that serology is more sensitive
than nested PCR using genomic DNA derived from PBMC
in detecting HHV8 infection. However, because patients
with CVID are unable to make specific antibodies and re-
ceive pooled human IgG as therapy, serologic studies cannot
be performed in this population. The sensitivity of nested
PCR using genomic DNA derived from PBMCs varies from
 50% in patients with KS to  80% in multicentric Castle-
man’s disease, an aggressive lymphoproliferative disorder (11,
12). Patients with CVID-GLILD have generalized lymph-
adenopathy with HHV8 infection in several organ systems.
Therefore, it is not surprising that the prevalence (67%) of
HHV8 infection as determined by nested PCR using ge-
nomic DNA from PBMCs in the CVID-GLILD cohort is
closer to Castleman’s disease than KS. The absence of
Figure 2. Detection of LANA-1 by IHC in tissue of CVID-GLILD 
patients. (A) IHC for LANA-1 of lung tissue from patient 11 with lym-
phocytis interstitial pneumonitis; 200 . The interstitium is expanded by 
a population of lymphocytes. Many of the cells express LANA-1 protein 
by IHC (brown staining). The inset (1,000 ) highlights the punctate 
nuclear staining that characterizes the presence LANA-1. (B) Same 
patient’s lung coimmunostained for CD3 (T cell marker, brown) and CD20 
(B cell marker, red). The mononuclear cells of the interstitial infiltrates 
are composed of a mixed infiltrate of B and T lymphocytes; 1,000 . 
(C) Same patient’s cervical lymph node. The biopsy was diagnosed as 
NHL. The IHC demonstrates abundant LANA-1–positive cells (brown); 
1,000 . (D) CD3 and CD20 coimmunostain of this patient’s lymph node 
biopsy. Most of the cells are red, indicating a predominance of B cells in 
this lymphoma. Occasional T lymphocytes are present (brown); 200 . 
The inset highlights the predominance of B cells; 1,000 . (E) A bone 
marrow biopsy from patient 10 demonstrates  50% of cells within the 
bone marrow are positive for LANA-1; 400  and 1,000 . (F) Transbron-
chial biopsy (patient 10) demonstrating patchy positivity by LANA-1 IHC, 
primarily within the lymphocytes of the bronchial wall, 200 . The inset 
demonstrates that  50% of the cells within this lymphoid aggregate 
are positive for LANA-1; 1000 . (G) Liver biopsy from a patient diag-
nosed with granulomatous hepatitis (patient 42). There are scattered 
hepatocytes positive for LANA-1; 200 . The inset shows positive nuclear 
staining in a hepatocyte nucleus; 1,000 . (H) Lung sample from a 
patient 58 diagnosed with a MALT-type lymphoma. The lung tissue was 
negative for LANA-1 by IHC, but positive by PCR; 200 .JEM VOL. 202, August 15, 2005 483
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HHV8 infection in groups other than the patients with
CVID is consistent with epidemiologic studies in the United
States that demonstrated a low prevalence of HHV8 infec-
tion (0.1–3%) in HIV-1 uninfected blood donors (13).
By QRT-PCR, the HHV8 viral load in the DNA from
PBMCs from CVID-GLILD patients ranged between 12
and 46 copies per  g of DNA. Assuming 106 cells yields  3
 g DNA, there were between 36 and 138 copies of HHV8
genome per 106 cells; this is similar to the HHV8 copy num-
bers observed in PBMCs of patients with KS and multicen-
tric Castleman’s disease (14, 15). The copy number of
HHV8 genome in the DNA from the tissue biopsies from
patients with CVID-GLILD were similar to that observed in
the tissues of other HHV8-induced diseases (16).
The high prevalence of HHV8 infection in the CVID-
GLILD cohort raises questions as to the source of the virus
and mode of infection. Intravenous immunoglobulin (IVIG)
is one possible source of transmission of HHV8. However,
the low prevalence (4.8%) of HHV8 infection in patients
with CVID, but without GLILD, and the absence of HHV8
infection in patients receiving IVIG for reasons other than
CVID argues against this possibility. Furthermore, one
HHV8-positive patient with CVID-GLILD (subject 29) first
received IVIG 3 yr before entry in the study. Sterilization
processes of IVIG over the last decade inactivate enveloped
viruses, such as HHV8 (17, 18). It is clear that further epide-
miologic studies are required to define the source and modes
of transmission for HHV8 infection in patients with CVID.
There are several possible reasons why HHV8 may be an
opportunistic pathogen in patients with CVID. The inability
to make specific antibodies along with the CD4 lymphopenia,
which was a prominent feature in patients with CVID-
GLILD, likely are important. However, we speculate that the
overproduction of inflammatory cytokines also may be in-
volved. Subgroups of patients with CVID overproduce in-
flammatory cytokines, such as IL-6 and TNF- . This dysregu-
lation of cytokine production has been attributed to
polymorphisms in the respective promoters of these cytokine
genes (19). The overproduction of TNF- , which occurs in
the subgroup of CVID patients with splenomegaly, granulo-
matous lung disease, and CD4 lymphopenia, has been hypoth-
esized to contribute to the formation and maintenance of
granulomas in these patients. We have not determined serum
levels of TNF-  in our cohort of CVID-GLILD patients, but
multisystemic granulomatous disease, CD4 lymphopenia, and
splenomegaly are prominent features in our CVID-GLILD
cohort of patients (reference 2; Table I).
Levels of inflammatory cytokines, such as IL-6 and TNF- ,
also are elevated in HHV8-induced malignancies (20). IL-6 en-
hances the replication of HHV8 and TNF-  and IL-6 may play
an important role in the promotion of HHV8-induced malig-
nancies (20). Polymorphisms within the promoter of the IL-6
gene have been linked to an increased propensity to develop KS
in people infected with HIV-1 and patients who have under-
gone renal transplants (21, 22). Therefore, we hypothesize that
the granulomatous and lymphoproliferative disease that is seen
in the CVID-GLILD cohort of patients, is due to the unique
interplay of HHV8 infection, cellular and humoral immunode-
ficiency, and polymorphisms within the promoters of inflam-
matory cytokine genes (e.g., TNF-  and IL-6). Studies are in
progress to address this possibility.
It is possible that other viruses, in addition to HHV8, are
involved in the pathogenesis of GLILD and lymphoprolifer-
ative disorders in CVID. For example, EBV and CMV are
opportunistic pathogens that have been implicated as a cause
of idiopathic pulmonary fibrosis (23, 24). EBV is found in a
small number of B cell lymphomas in patients with CVID,
including in one patient with an HHV8-negative, primary
effusion lymphoma (25). Prospective studies that examine
larger numbers of patients need to be performed to deter-
mine the role of these and other transformation-competent
viruses in the etiology of GLILD and lymphomas that occur
in the context of CVID.
In summary, our results suggest that HHV8 infection
may underlie the poor prognosis, diffuse interstitial lung dis-
ease, and increased prevalence of lymphoproliferative disor-
ders in patients with CVID. These observations raise the
possibility that HHV8 infection may be more prevalent than
previously believed, especially in people with primary im-
munodeficiencies. Lymphoproliferative disorders of unclear
etiology are increased in other primary immunodeficiencies;
this points out the importance of systematically studying the
prevalence of HHV8 infection in these disorders as well.
MATERIALS AND METHODS
Subjects. This study was approved by the Institutional Review Board at
National Jewish Medical and Research Center (Denver, CO). All subjects
signed informed consent before participation in the study. Patients with
CVID or receiving IVIG for reasons other than CVID were recruited
from the Adult or Pediatric Immunodeficiency Clinic at the National
Jewish Medical and Research Center. Normal blood donors were re-
cruited from healthy employees at National Jewish Medical and Research
Center. The criteria used for the diagnosis of CVID was as described pre-
viously (2). Patients with CVID were screened for HIV-1, hepatitis B vi-
rus, and HCV infection by PCR and were negative. Lymphocyte subsets
from peripheral blood of patients with CVID were enumerated by FACS
using the following CD antigens: total T cells (CD3 ), T helper cells
(CD3 /CD4 ), T suppressor/cytotoxic cells (CD3 /CD8 ), and B cells
(CD19 ). Lymphocyte numbers were expressed as cells per cubic millili-
ter and compared with established control values.
Nested and QRT-PCR and DNA sequencing. Genomic DNA from
PBMC was extracted using the PAXgene Blood DNA Validation Kit per the
manufacturer’s instructions (QIAGEN). Genomic DNA from tissue was iso-
lated from formalin-fixed, paraffin-embedded tissues as described previously
(26). For detection of HHV8 genome by nested PCR, primer sets were de-
signed to amplify two highly conserved open reading frames: ORF26 (minor
capsid antigen) and ORFK9 (viral interferon regulatory factor 1; reference 27).
The HHV8-ORF26 amplicon was sequenced using the ABI Prism 3100 Ge-
netic Analyzer (Applied Biosystems). QRT-PCR was performed as described
previously (28). Input DNA concentrations were normalized to human  -actin
using TaqMan  -Actin Control Reagents kit per the manufacturer’s instruc-
tions (Applied Biosystems).
IHC. IHC on tissue biopsies was performed using a monoclonal antibody
specific for HHV8–LANA-1 (Advanced Biotechnologies Inc.) as previously
described (10).HUMAN HERPESVIRUS 8 IN COMMON VARIABLE IMMUNODEFICIENCY | Wheat et al. 484
Statistical analysis. Fisher’s exact test was used to compare dichotomous
variables between the CVID-GLILD patients and CVID-control patients.
For quantitative variables, the Wilcoxon rank-sum test was used to compare
the two CVID groups. A two-tailed P value of less than 0.05 is considered
statistically significant.
Online supplemental material. Fig. S1 shows additional nested PCRs
for HHV8 using genomic DNA isolated from PBMCs on 10 additional nor-
mal blood donors. Fig. S2 shows additional positive (KS) and negative (lung,
liver, lymph node, bone marrow) IHC for LANA-1. Precautions that were
used to prevent contamination of genomic DNA obtained from patients, and
a complete description of the histopathologic studies of the malignant lymph
node obtained from patient 11 are included in online supplemental Materials
and methods. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20050381/DC1.
We thank Drs. L. Rosenwasser, S. Benedict, L. Borish, and J. Cook for thoughtful 
criticism of the manuscript and G. Cheatham for secretarial assistance.
This work was supported by a grant from the Immunodeficiency Foundation, 
the American Academy of Allergy, Asthma and Immunology and the Cancer League 
of Colorado (to J.M. Routes); and National Heart, Lung, and Blood Institute and 
Specialized Centers of Research HL67671 (to K.K. Brown and C.D. Cool).
 The authors have no conflicting financial interests.
Submitted: 18 February 2005
Accepted: 12 July 2005
REFERENCES
1. Cunningham-Rundles, C., and C. Bodian. 1999. Common variable im-
munodeficiency: clinical and immunological features of 248 patients.
Clin. Immunol. 92:34–48.
2. Bates, C.A., M.C. Ellison, D.A. Lynch, C.D. Cool, K.K. Brown, and
J.M. Routes. 2004. Granulomatous-lymphocytic lung disease shortens
survival in common variable immunodeficiency. J. Allergy Clin. Immunol.
114:415–421.
3. Chang, Y., E. Cesarman, M.S. Pessin, F. Lee, J. Culpepper, D.M.
Knowles, and P.S. Moore. 1994. Identification of new herpes-like DNA
sequences in AIDS associated Kaposi’s sarcoma. Science. 266:1865–1869.
4. Parravicini, C., B. Chandran, M. Corbellino, E. Berti, M. Paulli, P.S.
Moore, and Y. Chang. 2000. Differential viral protein expression in Ka-
posi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma,
primary effusion lymphoma, and multicentric Castleman’s disease. Am. J.
Pathol. 156:743–749.
5. Zong, J.C., C. Metroka, M.S. Reitz, J. Nicholas, and G.S. Hayward.
1997. Strain variability among Kaposi sarcoma-associated herpesvirus
(human herpesvirus 8) genomes: evidence that a large cohort of United
States AIDS patients may have been infected by a single common isolate.
J. Virol. 71:2505–2511.
6. Busse, P.J., S. Razvi, and C. Cunningham-Rundles. 2002. Efficacy of
intravenous immunoglobulin in the prevention of pneumonia in patients
with common variable immunodeficiency. J. Allergy Clin. Immunol. 109:
1001–1004.
7. Cunningham-Rundles, C. 1989. Clinical and immunologic analyses of
103 patients with common variable immunodeficiency. J. Clin. Immunol.
9:22–33.
8. Mechanic, L.J., S. Dikman, and C. Cunningham-Rundles. 1997. Granu-
lomatous disease in common variable immunodeficiency. Ann. Intern.
Med. 127:613–617.
9. Bechtel, J.T., Y. Liang, J. Hvidding, and D. Ganem. 2003. Host range of
Kaposi’s sarcoma-associated herpesvirus in cultured cells. J. Virol. 77:
6474–6481.
10. Cool, C.D., P.R. Rai, M.E. Yeager, D. Hernandez-Saavedra, A.E. Serls,
T.M. Bull, M.W. Geraci, K.K. Brown, J.M. Routes, R.M. Tuder, and
N.F. Voelkel. 2003. Expression of human herpesvirus 8 in primary pul-
monary hypertension. N. Engl. J. Med. 349:1113–1122.
11. Yamasaki, S., T. Iino, M. Nakamura, H. Henzan, K. Ohshima, M. Kiku-
chi, T. Otsuka, and M. Harada. 2003. Detection of human herpesvirus-8
in peripheral blood mononuclear cells from adult Japanese patients with
multicentric Castleman’s disease. Br. J. Haematol. 120:471–477.
12. Albrecht, D., T. Meyer, T. Lorenzen, A. Stoehr, R. Arndt, and A.
Plettenberg. 2004. Epidemiology of HHV-8 infection in HIV-positive
patients with and without Kaposi sarcoma: diagnostic relevance of serol-
ogy and PCR. J. Clin. Virol. 30:145–149.
13. Hengge, U.R., T. Ruzicka, S.K. Tyring, M. Stuschke, M. Roggendorf,
R.A. Schwartz, and S. Seeber. 2002. Update on Kaposi’s sarcoma and
other HHV8 associated diseases. Part 1: epidemiology, environmental
predispositions, clinical manifestations, and therapy. Lancet Infect. Dis.
2:281–291.
14. Lallemand, F., N. Desire, W. Rozenbaum, J.C. Nicolas, and V. Mare-
chal. 2000. Quantitative analysis of human herpesvirus 8 viral load using
a real-time PCR assay. J. Clin. Microbiol. 38:1404–1408.
15. Marcelin, A.G., I. Gorin, P. Morand, Z. Ait-Arkoub, J. Deleuze, J.P.
Morini, V. Calvez, and N. Dupin. 2004. Quantification of Kaposi’s sar-
coma-associated herpesvirus in blood, oral mucosa, and saliva in patients
with Kaposi’s sarcoma. AIDS Res. Hum. Retroviruses. 20:704–708.
16. Boivin, G., A. Gaudreau, and J.P. Routy. 2000. Evaluation of the hu-
man herpesvirus 8 DNA load in blood and Kaposi’s sarcoma skin lesions
from AIDS patients on highly active antiretroviral therapy. AIDS. 14:
1907–1910.
17. Dupon, M., B. Masquelier, C. Cazorla, G. Chene, B. Dumon, J.M.
Ragnaud, B. de Barbeyrac, C. Bebear, J.Y. Lacut, and H.J. Fleury. 1997.
Acquired immunodeficiency syndrome-associated Kaposi’s sarcoma and
human herpesvirus 8 DNA detection in serial peripheral blood mononu-
clear cell samples. Res. Virol. 148:417–425.
18. Trejo, S.R., J.A. Hotta, W. Lebing, C. Stenland, R.E. Storms, D.C. Lee,
H. Li, S. Petteway, and K.M. Remington. 2003. Evaluation of virus and
prion reduction in a new intravenous immunoglobulin manufacturing
process. Vox Sang. 84:176–187.
19. Mullighan, C.G., S.E. Marshall, M. Bunce, and K.I. Welsh. 1999. Varia-
tion in immunoregulatory genes determines the clinical phenotype of
common variable immunodeficiency. Genes Immun. 1:137–148.
20. Ensoli, B., M. Sturzl, and P. Monini. 2000. Cytokine-mediated growth
promotion of Kaposi’s sarcoma and primary effusion lymphoma. Semin.
Cancer Biol. 10:367–381.
21. Foster, C.B., T. Lehrnbecher, S. Samuels, S. Stein, F. Mol, J.A. Met-
calf, K. Wyvill, S.M. Steinberg, J. Kovacs, A. Blauvelt, et al. 2000. An
IL6 promoter polymorphism is associated with a lifetime risk of devel-
opment of Kaposi sarcoma in men infected with human immunodefi-
ciency virus. Blood. 96:2562–2567.
22. Gazouli, M., G. Zavos, I. Papaconstantinou, J.C. Lukas, A. Zografidis, J.
Boletis, and A. Kostakis. 2004. The interleukin-6-174 promoter poly-
morphism is associated with a risk of development of Kaposi’s sarcoma in
renal transplant recipients. Anticancer Res. 24:1311–1314.
23. Stewart, J.P., J.J. Egan, A.J. Ross, B.G. Kelly, S.S. Lok, P.S. Hasleton,
and A.A. Woodcock. 1999. The detection of Epstein-Barr virus DNA in
lung tissue from patients with idiopathic pulmonary fibrosis. Am. J.
Respir. Crit. Care Med. 159:1336–1341.
24. Tang, Y.W., J.E. Johnson, P.J. Browning, R.A. Cruz-Gervis, A. Davis,
B.S. Graham, K.L. Brigham, J.A. Oates Jr., J.E. Loyd, and A.A. Stecenko.
2003. Herpesvirus DNA is consistently detected in lungs of patients with
idiopathic pulmonary fibrosis. J. Clin. Microbiol. 41:2633–2640.
25. Sander, C.A., L.J. Medeiros, L.M. Weiss, T. Yano, M.C. Sneller, and E.S.
Jaffe. 1992. Lymphoproliferative lesions in patients with common variable
immunodeficiency syndrome. Am. J. Surg. Pathol. 16:1170–1182.
26. Lee, S.D., K.R. Shroyer, N.E. Markham, C.D. Cool, N.F. Voelkel,
and R.M. Tuder. 1998. Monoclonal endothelial cell proliferation is
present in primary but not secondary pulmonary hypertension. J. Clin.
Invest. 101:927–934.
27. Pan, L., L. Milligan, J. Michaeli, E. Cesarman, and D.M. Knowles.
2001. Polymerase chain reaction detection of Kaposi’s sarcoma-associ-
ated herpesvirus-optimized protocols and their application to my-
eloma. J. Mol. Diagn. 3:32–38.
28. White, I.E., and T.B. Campbell. 2000. Quantitation of cell-free and
cell-associated Kaposi’s sarcoma-associated herpesvirus DNA by real-
time PCR. J. Clin. Microbiol. 38:1992–1995.